Curevo Vaccine Announces $60 Million Series A Financing to Support Clinical Development of Next Generation Subunit Vaccines
Curevo’s lead program is CRV-101, an adjuvanted subunit vaccine for shingles, which has demonstrated robust immunogenicity and tolerability in…
